HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
May 21 2024 - 5:30AM
Business Wire
Filing of a U.S. IND for HFG1 is scheduled for
Q3/2024
HighField Biopharmaceuticals, a clinical stage company using
lipid-based therapeutics to treat cancer, diabetes and other
diseases, announced today that its abstract of preclinical data
evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic monkeys
has been accepted for a poster presentation at the American
Diabetes Association (ADA) 84th Scientific Sessions June 21-24,
2024, in Orlando, FL. The abstract also will be published on the
website of the ADA’s journal Diabetes.
“We are very excited to introduce our unique lipid nanoparticle
(LNP)-mRNA complex, HFG1, to the thousands of clinicians and
researchers attending this year’s Scientific Sessions from around
the world,” said HighField CEO and Scientific Founder Yuhong Xu,
Ph.D. “The components of HFG1’s LNP complex were designed to
provide consistent expression of a GLP-1R agonist for diabetes and
weight loss. We believe HFG1 will require far fewer injections than
existing GLP-1 products while providing steady-state agonist
activity.”
Abstract Title:
Preliminary Study of Efficacy and Duration
of an mRNA-Based GLP-1R Agonist in Diabetic Monkeys. (Poster
presentation number 1860-LB in category 12-B Clinical
Therapeutics-Incretin-Based Therapies).
Presenter:
Dr. Yuhong Xu, HighField CEO
Presentation:
Saturday, June 22, 2024, 12:30 pm – 1:30
pm EDT (The poster will be displayed Saturday, Sunday and Monday in
the Poster Hall; and at a Networking Reception Friday evening.)
About HighField Biopharmaceuticals
HighField is a clinical stage company focused on novel
applications of liposome constructs to disrupt existing
immuno-oncology and other disease technologies. The company also
has a research and development center and a GMP-compliant
production facility. HighField’s lead clinical development program
is HF1K16, a drug encapsulated immune modulating liposome
containing all-trans retinoic acid targeting myeloid-derived
suppressor cells for treatment of solid tumors. The company’s
pipeline also includes drug encapsulated immunoliposomes for solid
tumor cancers and lipid therapeutics for gene delivery and gene
therapy. For more information visit https://highfield.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521146324/en/
Media Contact: Dan Eramian Opus Biotech Communications
danieleramian@comcast.net 425-306-8716
Business Development Contact: Donald Wyatt HighField
Biopharmaceuticals dwyatt@hf-biopharm.com 206-356-8196